SCHEMBL3606704

SCHEMBL3606704

CC(C)(C)OC(=O)C1CNCC2C(=O)N(c3ccccc3Cl)CN12

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
CYBB P04839 1/20 0.34
NOX5 Q96PH1 1/20 0.34
NOX4 Q9NPH5 1/20 0.34
NOX1 Q9Y5S8 1/20 0.34
DRD2 P14416 3/20 0.33
DRD4 P21917 1/20 0.33
RAB9A P51151 2/20 0.33
CDK1 P06493 1/20 0.33
HSD17B10 Q99714 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
SSTR4 P31391 1/20 0.32
MAPT P10636 1/20 0.32
ADRB1 P08588 1/20 0.32
CCKBR P32239 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3597655 0.87 CASP1 (0.40) ALDH1A1CDK1TDP1SSTR4
SCHEMBL3599630 0.85 OPRM1 (0.35) DRD2CDK1
SCHEMBL3610030 0.85 MAPK1 (0.32) SMN1; SMN2MEN1KMT2ACDK1MAPT
SCHEMBL3604816 0.84 GPR119 (0.36) SSTR4
SCHEMBL3605596 0.83 ALDH1A1 (0.37) ALDH1A1MEN1KMT2ADRD2RAB9A
SCHEMBL3609805 0.83 ALDH1A1 (0.35) ALDH1A1SMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL3606996 0.82 KMT2A (0.39) ALDH1A1SMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL3608568 0.82 SLC6A2 (0.39) ALDH1A1SSTR4
SCHEMBL3607457 0.78 USP30 (0.44)
SCHEMBL3597127 0.78 DDB1 (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100004249-A1 Bicyclic heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-07 US disclosed
EP-2039695-A1 BICYCLIC HETEROCYCLIC COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2009-03-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004249-A1 Bicyclic heterocyclic compound and use thereof HTR2C, HTR5A, HTR2A ALDH1A1 1162/4885SMN1; SMN2 4009/4885MEN1 1716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.